News

Samsung Biologics Shows Strong Q3 Growth and Market Expansion

Samsung Biologics Shows Strong Q3 Growth and Market Expansion

Samsung Biologics Delivers Impressive Third Quarter Results

Samsung Biologics, a renowned global contract development and manufacturing organization (CDMO), has reported an outstanding financial performance in the third quarter of the fiscal year 2024. The company recorded consolidated revenue of KRW 1.2 trillion, which signifies a remarkable 15% increase in comparison to the previous year. Operating profit also showed strong growth, coming in at KRW 338.6 billion. Both figures reflect the company's commitment to excellence in biopharmaceutical development and manufacturing.

Performance Highlights for Q3 2024

Samsung Biologics attributed its success to several key factors. The utilization of its advanced facilities, particularly the newest Plant 4, played a crucial role in achieving these results. The overall efficiency and operational excellence across Plants 1 to 3 complemented the output from Plant 4, driving both revenue and profit significantly upward. The standalone revenue also impressively reached KRW 1.1 trillion with a standalone operating profit of KRW 444.7 billion.

Comprehensive Financial Overview

The company provides detailed figures showcasing its financial performance. For the third quarter, the revenue reached 1,187.1 KRW billion compared to 1,034.0 KRW billion in Q3 of the previous year, leading to a year-on-year change of +153.1 KRW billion (+14.8%). Meanwhile, operating profit increased by +20.1 KRW billion (+6.3%), rising from 318.5 KRW billion in Q3 2023 to 338.6 KRW billion in the latest results. This consistent growth is a testament to Samsung Biologics' strategic operational initiatives.

Rising Partnerships and Client Contracts

In addition to its remarkable financial performance, Samsung Biologics has fortified its partnerships with leading pharmaceutical companies. The organization now collaborates with 17 out of the top 20 global pharma clients. Furthermore, the total contract volume for the year has exceeded USD 3.3 billion, and the cumulative contract volume stands at USD 15.4 billion. This growth underlines the company’s reputation for delivering high-quality services, evidenced by securing over 335 regulatory approvals since its inception.

Future Outlook for Fiscal Year 2024

Looking ahead, Samsung Biologics remains optimistic about future revenue growth, raising its annual expectations to between 15% and 20%. The company anticipates this growth will be supported by the successful ramp-up of operations at Plant 4 and favorable exchange rates. Additionally, there are strong advancements in their ongoing strategic initiatives, including plans for a dedicated antibody-drug conjugate (ADC) facility and the anticipated operation of Plant 5 by April 2025.

Innovative Solutions and Technologies

Samsung Biologics is also advancing its service offerings to include solutions tailored for complex and high-concentration biopharmaceuticals. New platform launches such as S-AfuCHO™, S-OptiCharge™, and S-HiCon™ exhibit the company's innovative approach in generating afucosylated antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. These technologies aim to meet the evolving demands of clients and support their therapeutic objectives effectively.

Sustainability Initiatives in Operations

Committed to sustainability, Samsung Biologics has integrated eco-friendly practices into its operations. Recently, the company joined the Pharmaceutical Supply Chain Initiative as a Supplier Partner, reinforcing its commitment to sustainable supply chains as part of the Sustainable Market Initiative’s Health Systems Task Force. The focus on responsible business practices will continue shaping the company’s operational strategies moving forward.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is recognized as a premier end-to-end CDMO service provider. Its state-of-the-art facilities are designed to deliver comprehensive development and manufacturing solutions from cell line development to aseptic fill/finish. Engaging in continuous improvement, the company invests in advanced technologies such as ADC and mRNA production capabilities, aiming to expand its manufacturing capacity and operational efficiency.

Frequently Asked Questions

What were Samsung Biologics' revenue and profit in Q3 2024?

In Q3 2024, Samsung Biologics reported a consolidated revenue of KRW 1.2 trillion and an operating profit of KRW 338.6 billion.

How does Samsung Biologics maintain its competitive edge?

The company maintains its competitive edge through constant innovation, high-quality service delivery, and operational excellence across its plants.

What is the future growth projection for Samsung Biologics?

Samsung Biologics has raised its annual growth guidance to 15-20%, supported by successful operations at Plant 4 and strategic initiatives.

How many regulatory approvals has Samsung Biologics obtained?

Since its establishment, Samsung Biologics has obtained over 335 regulatory approvals, highlighting its commitment to quality.

What sustainability efforts is Samsung Biologics undertaking?

Samsung Biologics has partnered with the Pharmaceutical Supply Chain Initiative to enhance sustainable practices and contribute to eco-friendly supply chains.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 0

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 13

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 49

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 123

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 48

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Actions Alert: Key Deadlines for Investors to Note

Updated Category News Views 169

Class Actions Announced for Various Public Companies Investors should be aware of significant class action lawsuits impacting shareholders of Alarum Technologies Ltd. (NASDAQ: ALAR), Venture Global, Inc. (NYSE: VG), Constellation Brands, Inc. (NYSE: STZ), and The Trade Desk, Inc. (NASDAQ: TTD). These actions arise from allegations of false representations made by the...

Continue Reading
Wix Achieves Impressive Q1 2025 Financial Milestones

Updated Category News Views 733

Overview of Wix's Q1 2025 Performance Wix.com Ltd. (NASDAQ: WIX), a leader in the SaaS website-building space, has kicked off 2025 with a remarkable first quarter. The company reported total bookings of $511 million, marking a 12% increase year-over-year. This surge in bookings reflects a strong demand for its solutions and the effectiveness of its newly launched cohorts...

Continue Reading
XKIG Enhances Services with Acquisition of Thomas Contracting

Updated Category News Views 286

XKIG's Strategic Acquisition of Thomas Contracting Acquisition Strengthens Xylem Tree Experts' Position Across the Southeast XKIG, a leader in critical infrastructure services for power and gas utility sectors, recently announced an important acquisition. By integrating Thomas Contracting into its family of companies, XKIG is expanding its capabilities in vegetation...

Continue Reading
Apple iPhone 16 Sales Surge, Strong Competition from Samsung

Updated Category News Views 271

Apple iPhone 16 Sales Soar Amid Market Recovery Apple Inc. AAPL has celebrated a remarkable achievement with its iPhone 16 series, setting impressive sales records during the latest quarter. This surge in sales aligns with a rejuvenation in the global smartphone market, which is experiencing a significant rebound. Market Dynamics and Sales Performance According to the...

Continue Reading
Breakthrough MRD Data from Myriad Genetics at Cancer Conference

Updated Category News Views 260

Innovative Insights into MRD Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent name in molecular diagnostics and precision medicine, is set to unveil exciting new clinical findings related to their Precise MRD test at a significant annual meeting dedicated to cancer research. Presentation Highlights During the conference, Dr. Chad Tang from The University of Texas...

Continue Reading